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Coenzyme A (HMG-CoA) reductase inhibitors, or statins, inhibit endogenous cholesterol production by competitive inhibition of HMG-CoA reductase (HMGCR), the enzyme that catalyzes conversion of HMG-CoA to mevalonate, an early rate-limiting step in cholesterol synthesis. By reducing intracellular cholesterol production, statin treatment results in upregulation of low-density lipoprotein (LDL) receptors, leading to increased plasma clearance of LDL, primarily by the liver. In addition, statins can reduce hepatic secretion of the ApoB-containing lipoproteins, very low-density lipoprotein (VLDL) and LDL. As a result of these effects, statins can reduce plasma levels of atherogenic LDL by as much as 50%. Other effects of potential clinical significance include reductions in plasma triglycerides (TGs), increases in high-density lipoprotein (HDL) cholesterol (HDLC), an indicator of reduced cardiovascular disease (CVD) risk, and reductions in inflammatory markers, notably C-reactive protein (CRP) , that have been implicated in the development of CVD.
Statin therapy has been shown in numerous large clinical trials to reduce risk of cardiovascular events by 20-30%, an effect strongly related to the magnitude of LDL cholesterol (LDLC) reduction. 1, 2 On the basis of these findings, statin treatment in conjunction with lifestyle changes is indicated as first-line therapy for prevention of CVD in individuals who are considered to be at risk. 3 Adoption of current guidelines for plasma LDL reduction has led to the widespread and increasing use of statins, which are now the most prescribed class of drugs worldwide.
Clinical response to statin-mediated reduction of lipid and lipoprotein parameters is highly variable. 4 Although statin dosages are often adjusted once individual response to treatment is assessed, nearly a third of statin-treated patients do not meet their lipid-lowering goals. 5 In addition, adverse drug reactions (ADR), although rare, can be severe. Variability in response to statin therapy results from environmental and non-genetic factors, such as age, gender, diet, smoking status, and physical activity. Just as interindividual variability in plasma lipid and lipoprotein levels is governed by hereditary factors, it stands to reason that statin-response of these same parameters is also related to genetic heterogeneity. In fact, a recent study indicates clear population differences in rosuvastatin sensitivity between subjects of Caucasian, Chinese, Malaysian, and Indian decent all residing in Singapore that could not be accounted for by non-genetic factors. 6 This review will summarize studies examining genetic influences on statin efficacy and toxicity, and discuss the potential for this information to guide the optimal clinical use of these compounds.
Genetic influences on statin efficacy
Genes involved in pharmacokinetic response ( Figure 1 ) Genetic variations affecting statin pharmacokinetics can alter duration and magnitude of drug exposure, and hence both efficacy and toxicity ( Table 1) . Efficacy of statin response, measured by either lipid-lowering response or reduction in mortality, is dependent on hepatic rather than systemic statin exposure as these compounds undergo extensive first-pass clearance and the liver is the major site of action. 7 Although unlikely to affect statin efficacy, genetic variation causing alterations in systemic statin exposure may create susceptibility to adverse drug reactions. Genetic variations affecting hepatic exposure are more likely candidates for altering treatment efficacy.
There are six statin compounds currently on the market for use as cholesterol-lowering therapies: simvastatin, pravastatin, atorvastatin, lovastatin, fluvastatin, and rosuvastatin. The pharmacokinetic profiles of these compounds vary based on hydrophobicity. The more hydrophilic compounds, pravastatin in particular, require active transport into the liver, are less metabolized by the cytochrome P450 (CYP) family, and exhibit more pronounced active renal excretion; whereas the less hydrophilic compounds are transported by passive diffusion and are better substrates for both CYP enzymes and transporters involved in biliary excretion. [8] [9] [10] Given the differential involvement of pharmacokinetic genes in the metabolism of statin compounds, variation in these genes may aid in determining treatment choice.
Drug metabolizing enzymes affecting statin therapy
Statins undergo metabolism largely via the CYP3A (lovastatin, atorvastatin, simvastatin) or CYP2C (fluvastatin) families of metabolizing enzymes.
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Metabolism of these compounds may also be mediated, in part, by CYP2D6 or several glycosyltransferases (UGT1A1, UGT1A3, UGT2B7). 7, 12 Pravastatin and rosuvastatin interact minimally with metabolizing enzymes, are largely excreted unchanged, and are less likely to be affected by genetic variation in metabolizing enzymes.
Polymorphisms in genes encoding several of these enzymes have been examined for associations with variability in statin efficacy or systemic exposure. Within the CYP3A family, there are four independent reports of association with lipid lowering response. [13] [14] [15] [16] [17] [18] None of these observations have survived replication. Within the CYP2C family, the CYP2C9*3 haplotype has been associated with Figure 1 Candidate Genes in Pharmacokinetic Handling of Statins. Statins are dosed orally and enter the systemic circulation through enterocytes by active and passive mechanisms. Major organs of metabolism and elimination include the liver and, to a lesser extent, the kidney. Active transport across cellular membranes is executed by members of the solute carrier (SLC) and ATP-binding cassette (ABC) super families. Metabolism is catalyzed by cytochrome P450 (CYP) and glycosyltransferase (UGT) enzymes. All of these genes vary in their affinity for different statins and statin metabolites. For drug-specific views, please visit the Pharmacogenetics and Pharmacogenomics Knowledge Base (PharmGKB), http:// www.pharmgkb.org/search/pathway/statin/statin.jsp. duration of systemic exposure to fluvastatin, as measured by plasma area under the curve (AUC), but not with cholesterol reduction. 19 Contribution of genetic variation in CYP2D6 to simvastatin efficacy has also been studied with disparate results. An initial study suggested that lipid response to simvastatin treatment was inversely related to enzymatic activity. 20 This finding was replicated in one of two subsequent studies, both of which enrolled less than 100 subjects. [21] [22] [23] These data are further complicated by conflicting reports as to the significance of CYP2D6 metabolism in simvastatin clearance. [24] [25] [26] Conflicting conclusions from individual studies are largely due to limited sample size as underpowered studies are less likely to yield reproducible results. Two studies have recently appeared that attempted to address this issue: the Pravastatin Inflammation/CRP Evaluation (PRINCE) study, which examined associations of pravastatin efficacy with variation across 10 candidate genes in 1536 subjects; the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS), which examined associations between variation in 14 candidate genes and statin efficacy in 3916 subjects on various statins, half of whom were administered atorvastatin. 13, 17 Both of these studies included CYP3A4 and CYP3A5 as candidate genes, but neither identified significant associations. Whereas pravastatin is minimally metabolized by either CYP3A4 or CYP3A5, both enzymes metabolize atorvastatin. Hence, any influences of these genes on statin efficacy might have been expected to be detected in the ACCESS cohort.
Drug transporter proteins affecting statin therapy
Transporter proteins appear to be involved in hepatobiliary elimination of all statins as well as in absorption, distribution, and renal excretion of the more hydrophilic compounds. Although intestinal absorption of statins, all of which are dosed orally, is poorly studied, it is assumed to occur mainly by passive diffusion. There is some evidence for interaction with proton-dependent active transporters: specifically, SLCO2B1 in the case of pravastatin and SLC15A1 in the case of fluvastatin. 27, 28 SLCO2B1 is also implicated in hepatic uptake of pravastatin and has been examined for genetic contributions to interindividual variation in response to pravastatin. The main variant identified as having potential for pharmacogenetic response, marked by haplotype SLCO2B1*3, encodes a transporter of reduced function in vitro, but has not been associated with altered systemic drug exposure in vivo.
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Pravastatin also appears to be dependent on active transport for renal elimination, through SLC22A8 and SLC22A6.
Active transport is also important for hepatic uptake of statins, particularly pravastatin, and appears to be dependent on SLCO1B1 and to a lesser degree on SLCO2B1 and SLCO1B3. The most common genetic variants of SLCO1B1 (A388G, T521C) are represented alone or together as haplotypes *1A (neither), *1B (A388G), *5 (T521C), and *15 (A388G, T521C). Several single-dose pravastatin studies indicated that the *1B haplotype was associated with decreased plasma AUC, implying accelerated hepatocellular uptake, whereas the *5 and *15 haplotypes were associated with increased plasma AUC, indicating delayed hepatocellular uptake. 29, 31, 32 An additional haplotype, SLCO1B1*17, formed by the presence of a promoter variant (G-11187A), was also associated with elevated plasma AUC and reduced intracellular cholesterol synthesis.
33 SLCO1B1*5 carriers were reported to have attenuated plasma total cholesterol (TC) reduction in comparison to non-carriers. 34 Hepatobiliary excretion of statins is mediated by ABCC2 and ABCB1 as well as ABCG2 and ABCB11, all of which belong to a family of transporters known to interact with lipophilic xenobiotics. [35] [36] [37] [38] [39] [40] Variations in these transporters could alter duration of hepatic exposure, and therefore exposure to sites of action and to metabolizing enzymes. Variation in ABCC2, likely the largest contributor to biliary excretion of statins, is known to exhibit variation; however, this has been poorly studied in the context of statin transport. The only report notes that variation does not appear to alter plasma pravastatin AUC, 29 a finding consistent with the fact that this transporter is involved in hepatic export rather than import. ABCB1 encodes P-glycoprotein, which has been implicated in the transport of many drugs. A number of non-synonymous ABCB1variants responsible for altered protein function, including C1236T, C3435T and G2677T/A, have been tested for associations with the lipid-lowering efficacy of statins, without definitive results. 14, 41, 42 ABCC2 and ABCB1 are both involved in efflux of a wide variety of commonly prescribed drugs and conceivably functional variations in these transporters in conjunction with co-administration of interacting therapies could increase systemic drug exposures and risk for adverse drug reactions.
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Genes involved in pharmacodynamic response ( Figure 2 ) Genetic variations in any of the multiple genes involved in cholesterol metabolism, lipoprotein secretion, or lipoprotein clearance have the potential to affect the magnitude of plasma lipid-lowering response to statins and ultimately the extent to which these responses lead to reduction in CVD risks (Table 2 ). Additionally, statins are known to have pleiotropic non-lipidlowering effects that may influence CVD events via immune and inflammatory pathways or altered endothelial function. 43 Among likely mechanisms of interaction between statins and these pathways are alterations in production of cholesterol precursor molecules common to both lipid and non-lipid pathways. As production of these molecules is downstream to HMGCR-catalyzed mevalonate production, they may also be depleted by statin treatment.
Genetic variation in HMGCR, the direct target of statin therapy, is surprisingly understudied. The PRINCE study has reported two non-coding HMGCR variants in tight linkage disequilibrium (SNPs12 and 29) that associated with magnitude of LDLC response. Carriers of the haplotype constituted by these SNPs displayed smaller reductions in LDLC than noncarriers. 13 These were the only two SNPs of 148 found to meet the rigorous conditions for significance defined by this study, which included adjustments for multiple testing, similarity of effects in both the whole population and the Caucasian subpopulation (representing 88.7% of the subjects), and lack of association with baseline lipid levels. These criteria were intended to define variants strictly involved in pharmacogenetic response as well as to reduce likelihood of Type I error. Even so, association between these HMGCR SNPs and LDLC response failed to replicate in the AC-CESS cohort. 17 Whereas these initial findings may not be indicative of a true pharmacogenetic effect, there are other possible explanations for these discordant results. In particular, as neither SNP is predicted to alter function or expression of HMGCR, these SNPs may be in incomplete linkage disequilibrium (LD) with a causal variant. The extent of LD, as well as other background genetic or environmental influences, may differ in the two study populations. It may also be that there are differing pharmacogenetic effects of the HMGCR variant for pravastatin and atorvastatin.
Of the many genes involved in cholesterol biosynthesis and catabolism, polymorphisms in only two others have been examined for association with statin response. Squalene synthase (FDFT1) encodes a protein downstream to HMGCR in the cholesterol biosynthesis pathway. Variation in FDFT1 could also play a role in pleiotropic response to statin treatment, as it is upstream to production of molecules that may mediate these effects. Variation in this gene was not associated with lipid response to statin therapy. 13, 17 A promoter variant in CYP7A1, which encodes an enzyme that has a critical function in cholesterol oxidation and excretion, has been examined for association with diminished reduction in atorvastatin-induced For drug abbreviations, see Table 1 .
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In addition to the populations listed in Table 1 , the following studies were also examined: dyslipidemic patients (DL); coronary stent recipients (Stent) LDLC in two studies, with significant association seen only in one. 17, 44 Many genes involved in lipoprotein structure, secretion, and catabolism have been examined for influences on statin response. The most frequently studied of these are LDL receptor (LDLR), cholesterol ester transfer protein (CETP), and apolipoprotein E (ApoE). LDLR is a primary candidate for pharmacogenetic testing as it is directly implicated in the mechanism of statin-mediated LDL reduction. In addition, rare loss of function mutations in the gene encoding LDLR cause familial hypercholesterolemia (FH), a condition marked by strikingly elevated plasma cholesterol levels and increased risk of mortality. Statin-treated FH patients show variable responses to treatment in an LDLR mutation-dependent manner. Carriers of loss of function mutations appear more responsive than null function carriers. [45] [46] [47] [48] [49] More common, less dysfunctional LDLR genetic variants could alter response in non-FH hypercholesterolemic individuals. Several small studies suggest that this is true, although none of these associations were replicated in larger populations such as PRINCE or ACCESS. 13, 17, 50, 51 Genes involved in hepatic regulation of LDLR expression are also hypothesized to contribute to genetic variation in statin response. LDLR expression is highly regulated by many intracellular pathways, most significantly through transcriptional regulation by the sterol regulatory element binding protein (SREBP) family of transcription factors. These are sequestered in the endoplasmic reticulum under normal conditions and, when signaled by sterol depletion, are escorted by SREBP cleavage activating protein (SCAP) into the Golgi for proteolytic activation. Variations in SREBP1, SREBP2, and SCAP have been examined for genetic associations to statin response. SREBP1 promoter variant G-36D predicted the magnitude of statin-induced ApoAI elevation in one of two studies, whereas a polymorphism in SCAP has been reported to influence response of LDLC, TC, and TG. 52, 53 Association of SCAP variation with response of multiple lipid parameters suggests validity, but the SCAP variant associations have not replicated. 53, 54 Recently, a novel protease, PCSK9, has been implicated in LDLR protein degradation and variation in this gene was associated with basal plasma LDLC. [55] [56] [57] PCSK9 gain-offunction mutations causing increased degradation of LDLR and reduced clearance of plasma LDL were associated with higher pretreatment LDLC levels and attenuated statin-mediated reduction of LDLC. 55, 56 This newly discovered element of the lipoprotein regulatory system may be an important contributor to statin response.
The most closely examined gene connected with lipoprotein structure and metabolism is that encoding ApoE, a protein that resides on triglyceride-rich atherogenic lipoproteins as well as HDL, and interacts with LDLR to promote hepatic particle clearance. Three major variants of this form have been identified; e3, which encodes wild type protein, e2 and e4, both of which contain one non-synonymous variant causing altered protein function. The presence of variant isoforms causes altered particle clearance and is associated with hyperlipidemic states. Many studies have examined the contributions of these isoforms to statin-mediated response. The consensus is that e4 carriers appear to have attenuated lipid-lowering response, and e2 carriers have enhanced response. 13, 17, [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] Few studies have examined the effects of variations in genes encoding other apolipoproteins. There are reports that polymorphisms in APOB, the gene encoding the major structural protein in both LDL and triglyceride-rich lipoproteins, may alter LDLC response; whereas variation in the APOAI gene, encoding the major structural protein in HDL, may alter HDLC response. 13, 17, 50, 62, 66, [71] [72] [73] Modulation of lipoprotein lipid content is carried out by a series of proteins that act through mechanisms of inter-lipoprotein lipid transfers and lipolysis. CETP catalyzes the transfer of lipids between HDL and triglyceriderich lipoproteins. Variation in this gene, particularly a TaqIB variant located within intron 1, has been reported to be associated with plasma HDL concentration and CVD risk under basal conditions. 74, 75 Many studies have examined the influence of the TaqIB variant on statin response. Initial reports suggesting that TaqIB is associated with variation in HDLC response and CVD disease end points have failed to replicate. 13, [76] [77] [78] Boekholdt et al. 75 recently performed a meta-analysis, using data from 13 500 subjects across 10 trials but could not confirm this result. Although this variant may have a minor effect on response to statin therapy, it appears that the magnitude of the contribution is too small to easily distinguish from other sources of variation. Other lipid-modulating genes that have been studied include microsomal triglyceride transfer protein (MTP), which also encodes for a lipid transfer protein, and the lipase genes, lipoprotein lipase (LPL) and hepatic lipase (LIPC). Single studies have reported that a promoter variant in MTP is associated with triglyceride response and recurring risk of coronary events, an LPL variant may alter TC or HDLC response, and an LIPC variant may alter HDLC response. [79] [80] [81] [82] [83] [84] [85] Removal of cholesterol from peripheral cells requires active transport and is mediated by ABCA1. Preliminary pharmacogenetic analysis suggests that an ABCA1 haplotype may attenuate ApoAI response to statin treatment.
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ABCG5 and ABCG8 are transporters that act within the enterocyte to limit intestinal absorption, and within the hepatocyte to increase biliary excretion. 87, 88 Rare, loss of function mutations in these genes lead to sitosterolemia, a disorder characterized by hypercholesterolemia caused by increased intestinal cholesterol absorption and decreased biliary secretion. 89 Intestinal absorption of cholesterol is tightly regulated in conjunction with hepatic cholesterol synthesis to maintain homeostatic levels of systemic cholesterol. 90 LDLC resistance to statin therapy may be related to a compensatory increase in cholesterol absorption via upregulation of ABCG5 and ABCG8. [91] [92] [93] As such, these are major candidates for Clinical implications of statin pharmacogenomics LM Mangravite et al pharmacogenetic examination. To date, there is suggestive evidence that an ABCG8 variant is associated with LDLC response to statin treatment. 13, 17, 92 Pathways governing the pleiotropic or non-lipid response to statin therapy are under active investigation. There is evidence that these pathways contribute to statin-induced reductions in coronary events and mortality but their importance in this regard is not well established. As these pathways are incompletely characterized, it is difficult to identify candidate genes that may have pharmacogenetic influence. Nevertheless, a handful of studies have examined variation in putative response genes. As the mechanisms involved are independent of lipid-lowering effects, response in these studies tends to be defined by number of post-treatment coronary events or degree of atherosclerotic lesion progression. Replicate studies have been reported for only three genes: ACE, IGTB3, and TLR4. The gene encoding angiotensin converting enzyme (ACE) plays a role in regulation of blood pressure. An insertion/ deletion variant within the ACE gene has been reported to predict risk of recurring coronary events following statin treatment in several studies. [94] [95] [96] The IGTB3 gene encodes the platelet-specific fibrinogen receptor and variation in this gene has been associated under basal conditions with elevated risk of coronary disease. 94, 97 This increase in risk was reported to be abolished by statin treatment. 94, 97 The TLR4 gene encodes for toll-like receptor 4, which is involved in innate immunity. Carriers of a non-synonymous TLR4 variant (D299G) demonstrated reduced risk of post-treatment coronary events. 98, 99 None of the mechanisms for these associations is known. In short, studies regarding the role of variation in genes involved in non-lipid-lowering response to statins have not been definitive. A clearer understanding of the components of these pathways is required before a suitable list of candidate genes can be examined.
Although variation in genes involved in cholesterol biosynthesis or lipoprotein production and clearance are established contributors to variation in basal concentrations of plasma lipids, studies to date have not definitely demonstrated a link to variation in statin-mediated lipid response. The lack of success of studies aimed at discovering the genetic variation contributing to therapeutic response is due partly to methodological limitations, most notably lack of sufficient statistical power, and partly to the nature of the goal. Statin-mediated lipid reduction is a complicated system with many components. Individual examination of isolated genetic variants is unlikely to provide useful answers. Recent studies have moved to a multiple candidate gene strategy, but these have not yet examined the influence of interactions between these variations. This approach, as well as genome-wide association or linkage studies using larger populations, may prove more productive than previous studies.
Genetic influences on statinmediated adverse drug reactions
A particularly promising application of pharmacogenetics in statin therapy is the use of genetic pre-screening to identify subjects susceptible to adverse drug reactions. Although statin therapy is relatively well tolerated, with mild dyspepsia and gastrointestinal discomfort accounting for the majority of reported adverse reactions, more severe reactions can occur, notably severe hepatic dysfunction (B0.7% frequency) and skeletal myopathy (B0.1% frequency). These have been reported with all statins to varying degrees. 11 Although these events are rare, given the exceptional number of patients prescribed these drugs, the occurrences in real terms are considerable and serious enough to cause public concern. 100 Muscle biopsies from patients indicated that myopathy is defined on the cellular level by mitochondrial dysfunction, increased lipid storage, and ragged red muscle fibers. 101 Approximately 2-5% of myopathies lead to rhabdomyolosis, characterized by muscle destruction and myoglobinuria. 101 As myopathy is linked to elevated creatine kinase levels, monitoring of creatine kinase concentrations during statin treatment is recommended to identify cases before symptoms become severe. 102 Notably, not all cases of statin-induced myopathy are accompanied by elevated creatine kinase. 103 Risk and severity of myopathy with stain treatment, unlike statin efficacy, is related to magnitude and duration of systemic exposure. 102 Thus, the risk for this complication is more susceptible to any source of variation in pharmacokinetic parameters. Systemic exposure is affected by many nongenetic factors, including age, renal and hepatic function, smoking status, and concomitant medications. It is also likely to be affected by polymorphisms in the genes involved in pharmacokinetic handling of statins. Many of the studies discussed above examined the effect of variation in these genes on plasma AUC. Although this is not an appropriate predictor of efficacy, it may be a useful predictor of toxicity. Additionally, some of the transporters noted above, SLC22A6/8 and ABCB1, in particular, may be involved in transport of statins into skeletal muscle cells. 14, 17, 104 Current reports suggest that the SLC16 family of transporters, responsible for lactic acid transport across plasma membrane into muscle, also interacts with statins. 105, 106 Inhibition of SLC16A4, which is primarily expressed in skeletal but not cardiac myocytes, paralleling the site of clinical myopathy, is reported to attenuate statin-induced myopathy in vitro. 106, 107 This may be a good candidate gene for statin toxicity studies.
Pharmacogenetic analysis of statin myopathy is limited partly because the physiological mechanisms underlying statin-induced myopathy are not well understood. Myopathy may be linked to mitochondrial dysfunction, particularly within Complex I of the respiratory chain. 108 Initially thought to result from intracellular cholesterol depletion and alterations of membrane fluidity, myopathy is currently thought to be independent of cholesterol depletion and has been suggested to depend on depletion of Coenzyme Q, also a downstream derivative of mevalonate. 109 Coenzyme Q10 is a member of the mitochondrial respiratory chain as well as having involvement in maintaining cellular health. 110, 111 Both plasma and muscular concentrations of Coenzyme Q10 are depleted by statin therapy. 112, 113 Although Coenzyme Q10 supplements during statin therapy have been advocated for relieving muscle discomfort and reducing risk for myopathy, there is no conclusive evidence for their effectiveness. 114 Alternatively, statins may cause myopathy by impairing intracellular ion pumps, altering Na þ and Ca2 þ concentrations, and impairing cell conductance or inducing apoptosis. 115, 116 Pharmacogenetic analysis of statininduced myopathy is also limited by availability of cases. With a frequency of 0.1%, even the largest of the statin trials include only a handful of serious myopathy cases, making genetic association studies very difficult to power. Analyses to date are based on case studies or examination of a small number of subjects. Variation in CYP2D6 has been associated with decreased adherence to simvastatin therapy, although the metabolic significance of this enzyme in simvastatin clearance is under debate. 23, 25 The presence of the e4 allele of ApoE is associated with decreased adherence. 67 A case of rhabdomyolysisinduced death from cerivastatin exposure may have been caused by a loss of function mutation in CYP2C8 resulting in increased systemic exposure. 117 The SLCO1B1*15 haplotype, causing decreased hepatic uptake of pravastatin, is over-represented in subjects presenting with rhabdomyolysis. 118 Novel methods of recruitment will be necessary to compile populations better served to address the question of genetic variation in statin-induced ADR. Recently Wilke et al. 119 examined 68 cases of statin-induced myopathy within a retrospective casecontrol study of patients identified from the Marshfield Clinic patient population for association between CYP3A genotype and risk or severity of myopathy, as measured by serum CK level. Results indicated that severity but not risk was associated with the presence of two copies of the CYP3A5*3 haplotype. Ruano et al. examined 19 SNPs from 10 candidate genes involved in vascular homeostasis for association with statin-induced elevated serum CK levels and reported that polymorphisms in the gene for angiotensin II receptor 1(AGTR1), a multifunctional protein, and the gene encoding nitric oxide synthase 3 (NOS3), an enzyme involved in smooth muscle contraction and platelet aggregation, were associated with serum CK. 120 These two studies represent the first major examinations of genetic variation in statin-induced myopathy.
Summary of clinical implications
Although, statin pharmacogenetics is still in its infancy, the consensus based on current evidence is that genetic testing to assist in selecting a particular statin and/or dosing regimen is not clinically warranted. There are several reasons for this opinion. Statin therapy is so well tolerated in the majority of patients that the need to use additional testing to avoid deleterious side effects is relatively small. Moreover patients should be monitored for signs of hepatic or muscle toxicity to avoid more severe adverse reactions. In addition, patients on statin therapy should have lipid levels monitored so that submaximal response can be improved by increased dosage. Another major concern is that nearly all studies of pharmacogenetics of statin response reported to date have been underpowered and replication of positive results is lacking. Finally, most of these studies have examined associations of individual genetic polymorphisms with treatment response. Although genetic differences may prove a significant source of response variability, this is unlikely to be due to any single gene. Rather, the compound effects of multiple genetic variants are more likely to be responsible. Most studies have examined a small number of variants in a single or small number of genes -often one variant in one gene -and have reported the resultant outcomes based on small patient populations.
There are, however, other considerations that support the potential value of statin pharmacogenetic information. Identification of genes and genetic variants that influence statin responsiveness holds promise for identifying molecular components of physiological lipid and inflammatory pathways that mediate statin effects. However, the most important clinical benefits of statin pharmacogenetic knowledge would be based on identifying a set of genotypes that aid in predicting the outcomes of statin treatment in terms of reduced risk for cardiovascular events, coupled with reduced risk for serious ADRs. As studies to date have documented at most a 30% statin-mediated reduction in risk for CVD events and stroke, it would be valuable to have information on potential genetic influences on the likelihood of a beneficial outcome. However, a meaningful analysis of the genetic determinants responsible for statin efficacy and toxicity will require more comprehensive analysis of genome-wide variations in multiple large-scale populations. Until such information is available for either efficacy or safety, there is little reason to consider the use of genetic testing for guiding statin treatment.
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